20.90
Arrivent Biopharma Inc stock is traded at $20.90, with a volume of 192.38K.
It is up +0.19% in the last 24 hours and up +6.04% over the past month.
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$20.86
Open:
$20.88
24h Volume:
192.38K
Relative Volume:
0.64
Market Cap:
$847.89M
Revenue:
-
Net Income/Loss:
$-136.98M
P/E Ratio:
-5.199
EPS:
-4.02
Net Cash Flow:
$-126.63M
1W Performance:
+4.76%
1M Performance:
+6.04%
6M Performance:
+15.15%
1Y Performance:
-25.99%
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Name
Arrivent Biopharma Inc
Sector
Industry
Phone
240-780-6356
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AVBP
Arrivent Biopharma Inc
|
20.90 | 846.27M | 0 | -136.98M | -126.63M | -4.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-10-25 | Resumed | Goldman | Buy |
Mar-20-25 | Initiated | B. Riley Securities | Buy |
Mar-10-25 | Initiated | Guggenheim | Buy |
Jul-22-24 | Initiated | Oppenheimer | Outperform |
Apr-30-24 | Initiated | H.C. Wainwright | Buy |
Feb-20-24 | Initiated | Citigroup | Buy |
Feb-20-24 | Initiated | Goldman | Buy |
Feb-20-24 | Initiated | Jefferies | Buy |
View All
Arrivent Biopharma Inc Stock (AVBP) Latest News
Why ArriVent BioPharma Inc. stock is favored by pension fundsMarket Risk Analysis & Weekly High Potential Alerts - newser.com
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & Free Long-Term Investment Growth Plans - newser.com
What’s the recovery path for long term holders of ArriVent BioPharma Inc.July 2025 Institutional & Weekly Breakout Watchlists - newser.com
Analyzing ArriVent BioPharma Inc. with multi timeframe chartsJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com
Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com
How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN
Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com
Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com
ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria
ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz
ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks
Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener
ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener
ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times
Oncology Biotech ArriVent BioPharma Taps 25-Year Industry Veteran to Lead Lung Cancer Drug Launch - Stock Titan
Will earnings trigger a reversal in ArriVent BioPharma Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Institutional scanner results for Baker Hughes CompanyTrade Signal Summary & Daily Technical Forecast Reports - newser.com
Arrivent Biopharma Inc Stock (AVBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):